Case-Based Roundtable™

This roundtable series examines PARP inhibition as first-line maintenance therapy for patients with advanced ovarian cancer as discussed by participants at virtual live events.

This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.

This roundtable series assists in the evaluation of therapies for patients with metastatic triple-negative breast cancer as discussed by participants at virtual live events.

This roundtable series reviews the selection of regimens for patients with HER2-positive breast cancer as discussed by participants at virtual live events.

This roundtable series provides insight on risk assessment and multiple therapy combinations for patients with advanced renal cell carcinoma as discussed by participants at virtual live events.

This roundtable series evaluates genomic testing and NTRK-targeted treatment in patients with thyroid cancer as discussed by participants at virtual live events.

This roundtable series covers tyrosine kinase inhibition in the first line for patients with hepatocellular carcinoma discussed in virtual live events.

This roundtable series explores therapies for patients with castration-sensitive prostate cancer discussed in virtual live events.

This roundtable series assesses the use of treatments targeting MET exon 14 skipping mutations in patients with non–small cell lung cancer discussed in virtual live events.

This roundtable series reviews the use of Bruton’s tyrosine kinase inhibition as front-line treatment for patients with chronic lymphocytic leukemia discussed in virtual live events.

This roundtable series explores the use of later-line therapies in patients with diffuse large B-cell lymphoma discussed in virtual live events.

This roundtable series covers molecular imaging, prostate-specific membrane antigen testing, and treatment options for patients with castration-resistant prostate cancer discussed in virtual live events.